PUFA status and omega-3 fatty acid supplementation in hemodialysis patients: Pathophysiological aspects and clinical outcomes

Nutritional Therapy and Metabolism

Volumn 29, Issue 4, 2011, Pages 178-191

  Ristić Medić, Danijela ^a   Perunicić Peković, Gordana ^b   Rasić Milutinović, Zorica ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Chronic kidney disease; Hemodialysis; Phospholipid fatty acid; Polyunsaturated fatty acid

Indexed keywords

EID: 84867525316     PISSN: 18286232     EISSN: None     Source Type: Journal    
DOI: 10.5301/NTM.2012.9662     Document Type: Review

References (132)

1. Giannelli SV, Patel KV, Windham BG, Pizzarelli F, Ferrucci L, Guralnik JM. Magnitude of under ascertainment of impaired kidney function in older adults with normal serum creatinine. J Am Geriatr Soc 2007; 55: 816-23.
2. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260-9.
3. Baggio B, Musaachio E, Priante G. Polyunsaturated fatty acids and renal fibrosis: pathophysiologic link and potential clinical implications. J Nephrol 2005; 18: 362-7.
4. Lauretani F, Semba RD, Bandinelli S, et al. Plasma polyunsaturated fatty acids and the decline of renal function. Clin Chem 2008; 54: 475-81.
5. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006; 116: 288-96.
6. Koorts AM, Viljoen M, Kruger MC, et al. Red blood cell fatty acid profile of chronic renal failure patients receiving maintenance haemodialysis treatment. Prostaglandins Leukot Essent Fatty Acids 2002; 67: 13-8.
7. Arterburn LM, Hall EB, Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr 2006; 83: S1467-76.
8. De Caterina R, Madonna R, Bertolotto A, Schmidt EB. N-3 fatty acids in the treatment of diabetic patients: biological rationale and clinical data. Diabetes Care 2007; 30: 1012-26.
9. Rasic-Milutinovic Z, Perunicic G, Ristic D, et al. Effects of N-3 PUFAs supplementation on insulin resistance and inflammatory biomarkers in hemodialysis patients. Ren Fail 2007: 29: 321-9.
10. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors. Proc Natl Acad Sci 1997; 94: 4312-7.
11. Carpentier Y, Portois L, Malaisse W. N-3 fatty acids and the metabolic syndrome. Am J Clinic Nutr 2006; 83: S1449-504.
12. Kapoor R, Huang YS. Gamma linolenic acid: an antiinflammatory omega-6 fatty acid. Curr Pharm Biotechnol 2006; 7: 531-4.
13. Kim JW, Zou Y, Yoon S, et al. Vascular aging: molecular modulation of the prostanoid cascade by calorie restriction. J Gerontol A Biol Sci Med Sci 2004; 59: B876-85.
14. Friedman AN, Moe SM, Perkins SM, Li Y, Watkins BA. Fish consumption and omega-3 fatty acid status and determinants in long-term hemodialysis. Am J Kidney Dis 2006; 47: 1064-71.
15. Friedman A, Mo S. Dialysis patients review of the effects of omega-3 supplementation in dialysis patients. Clin J Am Soc Nephrol 2006; 1: 182-92.
16. Ahmad S, Dasgupta A, Kenny MA. Fatty acid abnormalities in hemodialysis patients: effect of L-carnitine administration. Kidney Int 1989; 36: S243-6.
17. Dasgupta A, Kenny MA, Ahmad S. Abnormal fatty acid profile in chronic hemodialysis patients: possible deficiency of essential fatty acids. Clin Physiol Biochem 1990; 8: 238-43.
18. Ramsay B, Cream JJ, Curtis JR, Manku MS, Stewart JC. Erythrocyte membrane docosahexanoic acid in haemodialysis patients on erythropoietin. Lancet 1992; 339: 1232-3.
19. Christensen J., Aaroe J, Knudsen N, Dideriksen K, Kornerup HJ, Dyerberg J. Heart rate variability and n-3 fatty acids in patients with chronic renal failure: a pilot study. Clin Nephrol 1998; 49: 102-6.
20. Varga Z, Karpati I, Paragh G, Buris L, Kakuk G. Relative abundance of some free fatty acids in plasma of uremic patients: relationship between fatty acids, lipid parameters, and diseases. Nephron 1997; 77: 417-21.
21. Peck LW, Monsen ER, Ahmad S. Effect of three sources of long-chain fatty acids on the plasma fatty acid profile, plasma prostaglandin E2 concentrations, and pruritus symptoms in hemodialysis patients. Am J Clin Nutr 1996; 64: 210-4.
22. Elshamaa MF, Sabry SM, Elghoroury EM, El-Saaid GS, Kandil D. Serum lipid profile and plasma fatty acids levels in hemodialysis pediatric patients: possible deficiency. Kidney 2010; 19: 316-23.
23. Madsen T, Christensen J., Svensson M, Witt PM, Toft E, Schmidt EB. Marine n-3 polyunsaturated fatty acids in patients with end-stage renal failure and in subjects without kidney disease: a comparative study. J Ren Nutr 2011; 21: 169-75.
24. Risitc V, Tepšic V, Ristic-Medic D, et al. Plasma and erythrocyte phospholipid fatty acids composition in Serbian hemodialysis patients. Ren Fail 2006; 28: 211-6.
25. Saifullah A, Watkins B., Saha C, Li Y, Moe SM, Friedman AN. Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients: a pilot study. Nephrol Dial Transplant 2007; 22: 3561-7.
26. Ristic-Medic D, Ristic G, Tepsic V. [Alfa linolenic acid and cardiovascular disease] [article in Serbian]. Med Pregl 2007; 60: S43-7.
27. Dobell E, Chan M, Williams P, Allman M. Food preferences and food habits of patients with chronic renal failure undergoing dialysis. J Am Diet Assoc 1993; 93: 1129-35.
28. Peck LW. Essential fatty acid deficiency in renal failure: can supplements really help? J Am Dietary Assoc 1997; 97 (Suppl 2): S150-3.
29. Taccone-Gallucci M, Lubrano R, Clerico A, Meloni C, Morosetti M, Meschini L. Administration of GSH has no influence on the RBC membrane: oxidative damage to patients on hemodialysis. ASAIO J 1992; 38: 855-7.
30. Duncan CJ. Calcium, oxygen radicals and cellular damage. Cambridge, UK: Cambridge University Press; 1991.
31. Avram M. Similarities between glomerular sclerosis in human renal biopsy specimens: a role for lipoprotein glomerulopathy. Am J Med 1989; 87: 39N-41N.
32. Nishizawa Y, Shoji T, Ishimura E, Inaba M, Morii H. Paradox of risk factors for cardiovascular mortality in uremia: is a higher cholesterol level better for atherosclerosis in uremia? Am J Kidney Dis 2001; 38 (Suppl 1): S4-7.
33. Axelsson TG, Irving, FF, Axelsson J. To eat or not to eat: dietary fat in uremia is the question. Division Disease Seminars in Dialysis 2010: 4: 383-8.
34. Seierstad SL, Seljeflot I, Johansen O, et al. Dietary intake of differently fed salmon: the influence on markers of human atherosclerosis. Eur J Clin Invest 2005; 35: 52-9.
35. Fusconi E, Pala V, Riboli E, et al. Relationship between plasma fatty acid composition and diet over previous years in the Italian centers of the European Prospective Investigation into Cancer and Nutrition (EPIC). Tumori 2003; 89: 624-35.
36. Shohet SB, Nathan DG. Incorporation of phosphatide precursors from serum into erythrocytes. Biochim Biophys Acta 1970; 202: 202-5.
37. Mulder E, Van Deenen LM, Metabolism of red-cell lipids: pathways for phospholipids renewal. Biochim Biophys Acta 1965; 106: 348-56.
38. Bjerve KS, Brubakk AM, Fougner KJ, Johnsen H, Midthjell K, Vik T. Omega-3 fatty acids: essential fatty acids with important biological effects and serum phospholipid fatty acids as markers of dietary omega-3 fatty acid intake. Am J Clin Nutr 1993; 57: 801S-6S.
39. Bross R, Nazanin N, Kovesdy CB, et al. Dietary assessment of individuals with chronic kidney disease. Semin Dial 2010; 4: 359-64.
40. De Gomez Dumm NT, Giammona AM, Touceda LA, Raimondi A. Lipid abnormalities in chronic renal failure patients undergoing hemodialysis. Medicina (B Aires) 2001; 61: 142-6.
41. Reaven P, Parthasarathy S, Grasse BJ, et al. Feasibility of using an oleate-rich diet to reduce the susceptibility of low-density lipoprotein to oxidative modification in humans. Am J Clin Nutr 1991; 54 701-6
42. Siscovick DS, Raghunathan TE, King I, et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995; 274: 1363-7.
43. Friedman A, Siddiqui R, Watkins B. Acute rise of omega-3 polyunsaturated fatty acids during hemodialysis treatment. J Ren Nutr 2008: 18: 301-3.
44. Vishwanath BS, Fux CA, Uehlinger DE, et al. Haemodialysis activates phospholipase A2 enzyme. Nephrol Dial Transplant 1996; 11: 109-16.
45. Stubbs CD, Smith AD. The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. Biochem Biophys Acta 1984; 779: 89-137.
46. Spector AA, Yorek MA. Membrane lipid composition and cellular function. J Lipid Res 1985; 26: 1015-35.
47. Clemens MR, Ruess M, Bursa Z, Dierck Waller H. The relationship between lipid composition of red blood cells and their susceptibility to lipid peroxidation. Free Rad Red Commun 1987; 3: 265-71.
48. Mills DE, Murphy M, Galley WR. Dietary fatty acids, membrane transport, and oxidative sensitivity in human erythrocytes. Lipids 1995; 30: 657-63.
49. Komidori K, Kamada T, Yamashita T, et al. Erythrocyte membrane fluidity decreased in uremic hemodialyzed patients. Nephron 1985; 40: 185-8.
50. Kaysen GA. Hyperlipidemia of chronic renal failure. Blood Purif 1994; 12: 60-7.
51. Nacamura N, Fujita T, Kumasaka R, et al. Serum lipid profile and plasma fatty acid composition in hemodialysis patients: comparison with chronic kidney disease patients. In Vivo. 2008; 22: 609-11.
52. An WS, Kim SE, Kim KH, et al. Comparison of fatty acid contents of erythrocyte membrane in hemodialysis and peritoneal dialysis patients. J Renal Nutr 2009; 19: 267-74.
53. Holman RT, Johnson SB, Bibus D, Spencer DC, Donadio JV. Essential fatty acid deficiency profiles in immunoglobulin A nephropathy. Am J Kidney Dis 1994; 23: 648-54.
54. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002; 106: 2747-57.
55. Harper R, Jacobson JA. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol 2008; 51; 2375-84.
56. Smith LA, Mozaffarian D, Willet W. Review of fats and fatty acid requirements and criteria for developing dietary guidelines. Ann Nutr Metab 2009; 55: 44-55.
57. Fassett RG, Gobe GC, Peake JM, Coombes JS. Omega-3 polyunsaturated fatty acids in the treatment of kidney disease. Am J Kidney Dis 2010; 56: 728-42.
58. Lauretani F, Maggio M, Pizzarelli S, Michelassi C, Ruggiero GP, Ceda S. Omega-3 and renal function in older adults. Curr Pharm Des 2009; 15: 4149-56.
59. Ewers B, Riserus U, Marckmann P. Effects of unsaturated fat dietary supplements on blood lipids, and on markers of malnutrition and inflammation in hemodialysis patients. J Ren Nutr 2009; 19: 401-11.
60. Ando M, Sanaka T, Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol 1999; 10: 2177-84.
61. Bowden RG, Jitomir J, Wilson RL, Gentile M. Effects of omega-3 fatty acid supplementation on lipid levels in endstage renal disease patients. J Ren Nutr 2009; 19: 259-66.
62. Bowden RG, Wilson RL, Deike E, Gentile M. Fish oil supplementation lowers C-reactive protein levels independent of triglyceride reduction in patients with end-stage renal disease. Nutr Clin Pract 2009; 24: 508-12.
63. Beavers KM, Beavers DP, Bowden RG, Wilson RL, Gentile M. Effect of over-the-counter fish-oil administration on plasma Lp(a) levels in an end-stage renal disease population. J Ren Nutr 2009; 19: 443-9.
64. Diskin CJ, Thomas CE, Zellner CP, Lock S, Tanja J. Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron 1990; 55: 445-7.
65. Donnelly SM, Ali MA, Churchill DN. Effect of n-3 fatty acids from fish oil on hemostasis, blood pressure, and lipid profile of dialysis patients. J Am Soc Nephrol 1992; 2: 1634-9.
66. Khajehdehi P. Lipid-lowering effect of polyunsaturated fatty acids in hemodialysis patients. J Ren Nutr 2001; 10: 191-5.
67. de Fijter CW, Popp-Snijders C, Oe LP, Tran DD, van der Meulen J, Donker AJ. Does additional treatment with fish oil mitigate the side effects of recombinant human erythropoietin in dialysis patients? Haematologica 1995; 80: 332-4.
68. Kirkegaard E, Svensson M, Strandhave C, Schmidt K, Jorgensen A, Hagstrup C. Marine n-3 fatty acids, atrial fibrillation and QT interval in haemodialysis patients. Br J Nutr 2011; 26: 1-7.
69. Maaloe T, Schmidt EB, Svensson M, Aardestrup IV, Christensen JH. The effect of n-3 polyunsaturated fatty acids on leukotriene B and leukotriene B production from stimulated neutrophil granulocytes in patients with chronic kidney disease. Prostaglandins Leukot Essent Fatty Acids 2011; 85: 37-41.
70. Mori TA, Beilin LJ, Burke V, Morris J, Ritchie J. Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Biol 1997; 17: 279-86.
71. Schmitz PG, McCloud LK, Reikes ST, Leonard CL, Gellens ME. Prophylaxis of hemodialysis graft thrombosis with fish oil: double blind, randomized, prospective trial. J Am Soc Nephrol 2002; 13: 184-90.
72. Svensson M, Christensen J., Solling J, Schmidt EB. The effect of n-3 fatty acids on plasma lipids and lipoproteins and blood pressure in patients with CRF. Am J Kidney Dis 2004; 44: 77-83.
73. Svensson M, Schmidt E, Jorgensen K, Christensen J. N-3 Fatty Acids as Secondary Prevention Against Cardiovascular Events in Patients Who Undergo Chronic Hemodialysis: a randomized, placebo-controlled intervention trial. Clin J Am Soc Nephrol 2006; 1: 780-6.
74. Svensson M, Schmidt EB, Jorgensen KA, et al. The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study. Nephrol Dial Transplant 2008; 23: 2918-24.
75. Svensson M, Schmidt EB, Jorgensen KA, Christensen JH. The effect of n-3 fatty acids on heart rate variability in patients treated with chronic hemodialysis. J Ren Nutr 2007; 17: 243-9.
76. Perunicic-Pekovic GB, Rasic ZR, Pljesa SI, et al. Effect of n-3 fatty acids on nutritional status and inflammatory markers in haemodialysis patients. Nephrology (Carlton) 2007; 12: 331-6.
77. Stenvinkel P. Inflammatory and atherosclerosis interactions in the depleted uremic patients. Blood Purif 2001; 19: 53-61.
78. Attman PO, Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia: relation to renal function and dialysis. Nephron 1991; 57: 401-10.
79. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Ren Physiol 2005; 290: F262-72.
80. Norbeck HE, Carlson LA. The uremic dyslipoproteinemia: its characteristics and relations to clinical factors. Acta Med Scand 1981; 209: 489-503.
81. Bergesio F, Monzani G, Ciuti R, et al. Lipids and apolipoproteins change during the progression of chronic renal failure. Clin Nephrol 1992; 38: 264-70.
82. Saland JM, Ginsberg HN. Lipoprotein metabolism in chronic renal insufficiency. Pediatr Nephrol 2007; 22: 1095-112.
83. Quaschning T, Krane V, Metzger T, Wanner C. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease. Am J Kidney Dis 2001: 38: S14-9.
84. Mittman N, Avram MM. Dyslipidemia in renal disease. Semin Nephrol 1996; 16: 202-13.
85. Ritz E. Why are lipids predictive of cardiovascular death in the dialysis patient? Miner Electrolyte Metab 1996; 22: 9-12.
86. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050-65.
87. Attman P, Samuelsson O, Alaupovi P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21: 573-92.
88. Gilett MP, Obineche EN, El-Rkhaimi M, Lakhani MS, Abdulle A, Sulaiman M. Lecithin:cholesterol acyltransferase, dyslipoproteinaemia and membrane lipids in uraemia. J Nephrol 2001; 6: 472-80.
89. Bagdade J, Casaretto A, Albers J. Effects of chronic uremia, hemodialysis, and renal transplantation on plasma lipids and lipoproteins in man. J Lab Clin Med 1976; 87: 38-48.
90. Vaziri ND, Deng G, Liang K. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant 1999; 14: 1462-6.
91. Vaziri ND, Moradi M. Mechanisms of dyslipidemia of chronic renal failure. Hemodial Int 2006; 10: 1-7.
92. Lapillonne A, Clarke SD, Heird WC. Polyunsaturated fatty acids and gene expression. Curr Opin Clin Nutr Metab Care 2004; 7: 151-6.
93. Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol 2006; 98: 27i-33i.
94. Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A 1997; 94: 4318-23.
95. Hu FB, Stampfer, MJ, Manson JE, et al. Dietary saturated fats and their food sources in relation to the risk of coronary heart disease in women. Am J Clin Nutr 1999; 70: 1001-8.
96. Jump DB. Dietary polyunsaturated fatty acids and regulation of gene transcription. Curr Opin Lipidol 2002; 13: 155-64.
97. Harris WS. N-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997; 65: 1645S-54S.
98. Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res 2003; 44: 455-63.
99. Ikeda I, Kumamaru J, Nakatani N, et al. Reduced hepatic triglyceride secretion in rats fed docosahexaenoic acid-rich fish oil suppresses postprandial hypertriglyceridemia. J Nutr 2001; 131: 1159-64.
100. Balk EM, Lichtenstein AH, Chung M, et al. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006; 189: 19-30.
101. Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol 2006; 98: 71-6.
102. Hooper L, Thomspson RL, Harrison RA. Omega-3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev 2004; 4: CD003177 Review.
103. Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol 2007; 99: 35C-43C.
104. Noori N, Dukkipati R, Kovesdy CP, et al. Dietary omega-3 fatty acid, ratio of omega-6 to omega-3 intake, inflammation, and survival in long-term hemodialysis patients. Am J Kidney Dis 2011; 58: 248-56.
105. Khan SA, Vanden Heuvel JP. Role of nuclear receptors in the regulation of gene expression by dietary fatty acids [review]. J Nutr Biochem 2003; 14: 554-567.
106. Calder PC. Dietary modification of inflammation with lipids. Proc Nutr Soc 2002; 61: 345-58.
107. De Caterina R, Libby P. Control of endothelial leukocyte adhesion molecules by fatty acids. Lipids 1996; 31 (Suppl): S57-63.
108. Calder PC. N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids 2003; 38: 343-52.
109. Endres S, Meydani SN, Ghorbani R, Schindler R, Dinarello CA. Dietary supplementation with n-3 fatty acids suppresses interleukin-2 production and mononuclear cell proliferation. J Leukoc Biol 1993; 54: 599-603.
110. Mantzioris E, Cleland LG, Gibson RA, Neumann MA, Demasi M, James MJ. Biochemical effects of a diet containing foods enriched with n-3 fatty acids. Am J Clin Nutr 2000; 72: 42-8.
111. Geelen A, Brouwer IA, Schouten EG, Kluft C, Katan MB, Zock PL. Intake of n-3 fatty acids from fish does not lower serum concentrations of C-reactive protein in healthy subjects. Eur J Clin Nutr 2004; 58: 1440-2.
112. Rasić-Milutinović Z, Perunicić-Peković G, Ristić-Medić D, Popović T, Glibetić M, Djurić DM. Insulin resistance and chronic inflammation are associated with muscle wasting in end-stage renal disease patients on hemodialysis. Gen Physiol Biophys 2009; 28: 184-9.
113. Perunicic-Pekovic G, Pljesa S, Rasic-Milutinovic Z, Stankovic S, Ilic M, Maletic R. Inflammatory cytokines and malnutrition as related to risk for cardiovascular disease in hemodialysis patients. Can J Physiol Pharmacol 2008; 86: 205-9.
114. Graber R, Sumunda C, Nunez EA. Fatty acid and cell signal transduction. J Lipid Mediat Call Signal 1994: 9: 91-116.
115. Di Marzo V. Arachidonic acid and eicosonoids as target and effectores in second messenger interactions. Prostanlandins Leukot Essent Fatty Acids 1995; 53: 239-54.
116. Das UN. Long-chain polyunsaturated fatty acids interact with nitric oxide, superoxide anion, and transforming growth factor-beta to prevent human essential hypertension. Eur J Clin Nutr 2004; 58: 195-203.
117. Das UN, Mohan IK, Raju TR. Effect of corticosteroids and eicosapentaenoic acid/docosaheksaenoic acid on pro-oxidant and antioxidant status and metabolism of essential fatty acids in patients with glomerular disorders. Prostaglandins Leukot Essent Fatty Acids 2001; 65: 197-203.
118. Ikizler TA, Morrow JD, Roberts LJ, et al. Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol 2002; 58: 190-7.
119. Panzetta O, Cominacini L, Garbin U, et al. Increased susceptibility of LDL to in vitro oxidation in patients on maintenance hemodialysis: effects of fish oil and vitamin E administration. Clin Nephrol 1995; 44: 303-9.
120. Bonanome A, Biasia F, De Luca M, Munaretto G, Biffanti S, Pradella M, Pagnan A: n-3 fatty acids do not enhance LDL susceptibility to oxidation in hypertriacylglycerolemic hemodialyzed subjects. Am J Clin Nutr 1996; 63: 261-6.
121. Peuchant E, Carbonneau MA, Dubourg L, Thomas MJ, Perromat A, Vallot C, Clerc M. Lipoperoxidation in plasma and red blood cells of patients undergoing haemodialysis: vitamins A, E, and iron status. Free Radic Biol Med1994; 16: 339-46.
122. Cartwright IJ, Pockley AG, Galloway JH, Greaves M, Preston FE. The effects of dietary omega-3 polyunsaturated fatty acids on erythrocyte membrane phospholipids, erythrocyte deformability and blood viscosity in healthy volunteers. Atherosclerosis 1985; 55: 267-81.
123. Bowden RG, Wilson RL, Gentile M, Ounpraseuth S, Moore P, Leutholtz BC. Effects of omega-3 fatty acid supplementation on vascular access thrombosis in polytetrafluoroethylene grafts. J Ren Nutr 2007; 17: 126-31.
124. Irish A, Dogra G, Mori T, et al. Preventing AVF thrombosis: the rationale and design of the Omega-3 Fatty Acids (Fish Oils) and Aspirin in Vascular access Outcomes in Renal Disease (FAVOURED) study. BMC Nephrol 2009; 10: 1.
125. Mori TA, Burke V, Puddey I, Irish A, et al. The effects of omega 3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial. J Hypertens 2009; 27: 1863-72.
126. Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation 1993; 88: 523-33.
127. McGiff JC, Quilley J. 20-Hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids and blood pressure. Curr Opin Nephrol Hypertens 2001; 10: 231-7.
128. Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: meta regression analysis of randomized trials. J Hypertens 2002; 20: 1493-9.
129. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Laniere N; European Uremic Toxin Working Group. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-56.
130. Sarnak MJ, Levey AS, Schoolwerth AC, et al. American heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology and epidemiology and prevention: kidney disease as a risk factor for development of cardiovascular disease. AHA scientific statement. Circulation 128: 2154.
131. Friedman AN, Saha C, Watkins BA. Feasibility study of erythrocyte long-chain omega-3 polyunsaturated fatty acid content and mortality risk in hemodialysis patients. J Ren Nutr 2008; 18: 509-12.
132. Kutner NG, Clow PW, Zhang R, Aviles X. Association of fish intake and survival in a cohort of incident dialysis patients. Am J Kidney Dis 2002; 39: 1018-24.